Edition:
India

CTI Biopharma Corp (CTIC.OQ)

CTIC.OQ on NASDAQ Stock Exchange Capital Market

2.35USD
20 Jul 2018
Change (% chg)

$0.08 (+3.52%)
Prev Close
$2.27
Open
$2.27
Day's High
$2.36
Day's Low
$2.17
Volume
332,316
Avg. Vol
139,251
52-wk High
$5.36
52-wk Low
$2.17

Chart for

About

CTI BioPharma Corp. is a biopharmaceutical company focused on the acquisition, development and commercialization of targeted therapies covering a spectrum of blood-related cancers to patients and healthcare providers. The Company is primarily focused on commercializing PIXUVRI in select countries in the European Union, for... (more)

Overall

Beta: 0.62
Market Cap(Mil.): $140.98
Shares Outstanding(Mil.): 42.98
Dividend: --
Yield (%): --

Financials

BRIEF-Cti Biopharma Reports Q1 EPS Loss Per Share Of $0.08

* AS OF MARCH 31, 2018, CASH AND CASH EQUIVALENTS TOTALED $104.6 MILLION, COMPARED TO $43.2 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage:

04 May 2018

BRIEF-Children's Hospital Of Philadelphia Foundation To Engage In Dialogue With Spark Therapeutics To Be Allowed To Designate At Least 1 Board Member

* CHILDREN'S HOSPITAL OF PHILADELPHIA FOUNDATION - TO ENGAGE IN DIALOGUE WITH SPARK THERAPEUTICS TO BE ALLOWED TO DESIGNATE AT LEAST 1 BOARD MEMBER

09 Mar 2018

BRIEF-CTI Biopharma Q4 Loss Per Share $0.33

* CTI BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

08 Mar 2018

BRIEF-Tempest Therapeutics Inc Says It Has Raised $25.2 Million In Equity Financing

* TEMPEST THERAPEUTICS, INC FILES TO SAY IT HAS RAISED $25.2 MILLION IN EQUITY FINANCING - SEC FILING​

02 Mar 2018

BRIEF-Growth Equity Opportunities Fund Reports 6.0 Pct Stake In CTI Biopharma

* GROWTH EQUITY OPPORTUNITIES FUND V LLC REPORTS 6.0 PERCENT STAKE IN CTI BIOPHARMA CORP AS OF FEB 8 - SEC FILING

21 Feb 2018

BRIEF-CTI BioPharma Prices Underwritten Public Offering Of $60 Million Of Common Stock

* CTI BIOPHARMA PRICES UNDERWRITTEN PUBLIC OFFERING OF $60 MILLION OF COMMON STOCK

09 Feb 2018

BRIEF-CTI Biopharma Announces Launch Of Follow-On Offering

* CTI BIOPHARMA CORP - INTENDS TO USE NET PROCEEDS OF OFFERING TO COMPLETE PAC203 CLINICAL TRIAL, COMPLETE REVIEW OF PACRITINIB MAA BY EMA, AMONG OTHERS Source text for Eikon:

05 Feb 2018

BRIEF-CTI Biopharma Provides Corporate And European Regulatory Update

* CTI BIOPHARMA PROVIDES CORPORATE AND EUROPEAN REGULATORY UPDATE

26 Jan 2018

Canada's Aurora Cannabis to buy rival to create world's most valuable weed firm

Canada's No. 2 marijuana producer Aurora Cannabis Inc has agreed to buy smaller rival CanniMed Therapeutics Inc for C$1.1 billion ($852 million) as companies jostle to benefit from the country's legalization of recreational marijuana use later this year. | Video

25 Jan 2018

Canada's Aurora Cannabis to buy rival to create world's most valuable weed firm

Canada's No. 2 marijuana producer Aurora Cannabis Inc has agreed to buy smaller rival CanniMed Therapeutics Inc for C$1.1 billion ($852 million) as companies jostle to benefit from the country's legalization of recreational marijuana use later this year. | Video

25 Jan 2018

Earnings vs. Estimates